Hemogenyx Pharmaceuticals PLC Presentation at Cancer Immunotherapy Conference (4516O)
January 30 2019 - 2:00AM
UK Regulatory
TIDMHEMO
RNS Number : 4516O
Hemogenyx Pharmaceuticals PLC
30 January 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Hemogenyx to Present at the 'Cancer Immunotherapy: Mechanistic
Insights to Improve Clinical Benefit' conference
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce
that its CEO Dr Vladislav Sandler will present at the conference
'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical
Benefit'. The conference is taking place in Whistler, Canada from
10 to 14 March 2019 and is organized within the Keystone Symposia
on Molecular and Cellular Biology (https://goo.gl/Egxj3V).
Dr Sandler's presentation is entitled 'A Novel Anti-FLT3-CD3
Bispecific Antibody for the Treatment of Acute Myeloid Leukemia and
Conditioning of Patients for Hematopoietic Stem Cell
Transplantation'. The presentation will highlight the fact that,
despite numerous advances in understanding the biology and
pathogenesis of acute myeloid leukemia (AML), treatment remains
unsatisfactory and that relapsed or refractory AML is nearly
universally fatal. The presentation will describe the state of
development of the Company's CDX antibodies and their potential
benefit for the treatment of AML and conditioning of patients for
hematopoietic stem cell (HSC) transplantation.
Keystone Symposia on Molecular and Cellular Biology
(https://goo.gl/epxTuf) is a nonprofit organization with a 47-year
history of convening open, peer-reviewed conferences that connect
the scientific community and accelerate life science discovery. Its
Scientific Advisory Board is comprised of eminent biomedical
scientists whose expertise derives from academia, industry, and the
government (https://goo.gl/GtwUjT).
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Via Walbrook PR
Officer & Co-Founder
Sir Marc Feldmann, Executive Chairman
Northland Capital Partners Limited Tel: +44 (0)20 3861 6625
Matthew Johnson, Vadim Alexandre
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Relations) Tel: +44 (0)20 7933 8780 or
hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned US operating
subsidiary, Hemogenyx LLC, located in New York City at its
state-of-the-art research facility ("Hemogenyx").
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMMGZMVLGGLZM
(END) Dow Jones Newswires
January 30, 2019 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024